Mannitol for cerebral oedema after acute intracerebral haemorrhage (MACE-ICH): protocol for a prospective, randomised, open-label, blinded-endpoint phase IIb trial
(2025)
Journal Article
Krishnan, K., Grace, E., Woodhouse, L., Roffe, C., Dawson, J., England, T. J., Hewson, D. W., Dineen, R. A., Law, Z. K., Pszczolkowski, S., Wells, K., Buck, A., Craig, J., Havard, D., Macleod, M. J., Werring, D. J., Doubal, F., Sprigg, N., & Bath, P. (2025). Mannitol for cerebral oedema after acute intracerebral haemorrhage (MACE-ICH): protocol for a prospective, randomised, open-label, blinded-endpoint phase IIb trial. BMJ Open, 15(7), Article e103776. https://doi.org/10.1136/bmjopen-2025-103776
Background Acute intracerebral haemorrhage (ICH) is devastating with a 1 month mortality rate of ~40%. Cerebral oedema can complicate acute ICH and is associated with poor outcome. In patients with large ICH, the accompanying swelling increases mass... Read More about Mannitol for cerebral oedema after acute intracerebral haemorrhage (MACE-ICH): protocol for a prospective, randomised, open-label, blinded-endpoint phase IIb trial.